Me still merchandises its ancestry, health analysis, and the Total Health annual package on a scale from $99 to $999 annually. Lemonaid entered the hot GLP-1 prescribing and support business in 2024, ...

Tempus AI stock had its best day on record on Tuesday after the medical tech company launched an AI-powered health concierge ...

Tempus AI says the app, olivia, is designed to centralize patients’ health data and make it accessible through artificial ...

Moderna received a $590 million award from the U.S. government to speed development of a vaccine that could be used to fight bird flu.

Investing.com -- Genetic testing firm 23andMe is reportedly considering the sale of its telehealth division, Lemonaid Health, according to Business Insider. The company, which has faced financial ...

Me (ME) has been quietly exploring a possible sale of its telehealth business, Lemonaid, according to Business Insider.Stay Ahead of the ...

Struggling genetic testing 23andMe is looking for a buyer for the virtual care business it acquired in 2021, Business Insider ...

SEC sues Elon Musk over Twitter purchase, Microsoft says businesses should get quantum ready in 2025, and more news to start ...

What initially stands out to me about Hims & Hers is the company's distinct branding and feel of luxury, which is evident on ...

Over the past year, Universal Health shares have gained 17.2%, significantly outpacing the industry average gain of 4.5%. However, the stock has underperformed compared to the broader S&P 500 Index.

Crude oil futures settle higher on the first trading day of the year amid some optimism about the outlook for the Chinese economy, while outsized U.S. product inventory builds looked bearish. U.S ...